April 1, 2019
Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1
Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas Selumetinib Is a MEK 1/2 Inhibitor…